EGF Theramed Health (AUH) Stock Price & Analysis
AUH Stock Chart & Stats
- Day’s Range
- EUR 0.03 - EUR 0.03
- 52-Week Range
- EUR 0.01 - EUR 0.08
- Previous Close
- EUR 0.03
- Volume
- 0
- Average Volume (3M)
- 34
- Market Cap
- EUR 297.71K
- Enterprise Value
- EUR 1.17M
- Total Cash (Recent Filing)
- EUR 10.47K
- Total Debt (Recent Filing)
- EUR 1.63M
- Price to Earnings (P/E)
- ―
- Beta
- -1.58
- Next Earnings
- Dec 01, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash Generation
The shift to slightly positive operating and free cash flow in 2025 signals emerging cash generation after several years of negative flows. Although the amount is small, sustained positive cash flow would reduce near-term financing needs and provide a foundation for incremental investment or product commercialization.
Reduced Net Loss Trend
A multi-year reduction in net losses from the 2020 peak indicates the company has narrowed its operating deficit. Persistent improvement in loss magnitude reflects progress toward operational stabilization, which is necessary for eventual profitability once revenue generation or scaling initiatives commence.
Cost Discipline Signal
The documented improvement in cash flow implies management enacted cost controls or restructuring to conserve cash. Effective and durable cost discipline can extend runway, lower dilution risk from future financings, and allow more time to pursue product development or market entry strategies.
Bears Say
No Reported Revenue
Zero reported revenue across the available periods shows the company lacks commercialized products or monetization. Without recurring revenue, long-term viability depends on successful product launches or continual external funding, substantially increasing execution and dilution risk for stakeholders.
Negative Shareholders' Equity
Negative equity combined with a tiny asset base and meaningful debt denotes structural solvency pressure. This severely limits financial flexibility, raises the probability of recapitalization or dilution, and constrains the firm's ability to invest in growth or withstand protracted development timelines.
Persistent Operating Losses
Ongoing negative EBIT/EBITDA and a larger 2025 loss indicate the business has not achieved operating leverage or profitability. Continued operating deficits will deplete cash reserves absent material revenue growth or fresh capital, weakening competitive position and limiting R&D or commercialization capacity.
EGF Theramed Health News
AUH FAQ
What was EGF Theramed Health’s price range in the past 12 months?
What is EGF Theramed Health’s market cap?
When is EGF Theramed Health’s upcoming earnings report date?
How were EGF Theramed Health’s earnings last quarter?
Is EGF Theramed Health overvalued?
Does EGF Theramed Health pay dividends?
What is EGF Theramed Health’s EPS estimate?
How many shares outstanding does EGF Theramed Health have?
What happened to EGF Theramed Health’s price movement after its last earnings report?
Which hedge fund is a major shareholder of EGF Theramed Health?
What is the TipRanks Smart Score and how is it calculated?
Company Description
EGF Theramed Health
EGF Theramed Health Corp. focuses on providing psychedelic-based therapies to address various mental health challenges. The company's products are specifically utilized in the treatment of conditions such as intractable depression, anxiety disorders, post-traumatic stress disorder (PTSD), and general depression. Established in 2011, this firm operates from its main headquarters in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Connor Yuen
- Employees
- 0
- Website
- www.egftheramedhealth.com
- Address
- Pacific Centre, Vancouver, BC, V7Y 1C3, CA
EGF Theramed Health (AUH) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 3 | 4 |
| Technical Analysis | 2 | 3 | 4 |
| Moving Averages | 12 | 0 | 0 |
